These findings collectively suggest that SHYZD may enhance learning and memory abilities in AD by modulating the NF-κB/NLRP3 pathway to inhibit inflammasome activation and mitigate the neuroinflammatory response. This evidence concerns the gene NLRP3 and Alzheimer disease.